Answers are grounded in this paper and cite their sources.
Exon skipping is a promising therapeutic for Duchenne muscular dystrophy patients, but the road to drug approvals is foggy and may require more early-stage derisking and regulatory guidance.
No takes yet. Share an insight, caveat, or question.
Hoffman et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: